Oberste MS - Search Results

1

Progress Toward Poliovirus Containment Implementation - Worldwide, 2018-2019.

Moffett DB, Llewellyn A, Singh H, Saxentoff E, Partridge J, Iakovenko M, Roesel S, Asghar H, Baig N, Grabovac V, Gurung S, Gumede-Moeletsi N, Barnor J, Theo A, Rey-Benito G, Villalobos A, Boualam L, Swan J, Sutter RW, Pandel E, Wassilak S, Oberste MS, Lewis I, Zaffran M; MEng. Moffett DB, et al. Among authors: oberste ms. MMWR Morb Mortal Wkly Rep. 2019 Sep 27;68(38):825-829. doi: 10.15585/mmwr.mm6838a3. MMWR Morb Mortal Wkly Rep. 2019. PMID: 31557146 Free PMC article.

2

Progress toward global interruption of wild poliovirus transmission, 2010-2013, and tackling the challenges to complete eradication.

Wassilak SG, Oberste MS, Tangermann RH, Diop OM, Jafari HS, Armstrong GL. Wassilak SG, et al. Among authors: oberste ms. J Infect Dis. 2014 Nov 1;210 Suppl 1(0 1):S5-15. doi: 10.1093/infdis/jiu456. J Infect Dis. 2014. PMID: 25316873 Free PMC article. Review.

3

Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication.

McKinlay MA, Collett MS, Hincks JR, Oberste MS, Pallansch MA, Okayasu H, Sutter RW, Modlin JF, Dowdle WR. McKinlay MA, et al. Among authors: oberste ms. J Infect Dis. 2014 Nov 1;210 Suppl 1:S447-53. doi: 10.1093/infdis/jiu043. J Infect Dis. 2014. PMID: 25316866 Review.

4

Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.

Kalkowska DA, Pallansch MA, Wilkinson A, Bandyopadhyay AS, Konopka-Anstadt JL, Burns CC, Oberste MS, Wassilak SGF, Badizadegan K, Thompson KM. Kalkowska DA, et al. Among authors: oberste ms. Risk Anal. 2021 Feb;41(2):329-348. doi: 10.1111/risa.13622. Epub 2020 Nov 10. Risk Anal. 2021. PMID: 33174263 Free PMC article.

5

Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan.

Saleem AF, Yousafzai MT, Mach O, Khan A, Quadri F, Weldon WC, Oberste MS, Zaidi SS, Alam MM, Sutter RW, Zaidi AKM. Saleem AF, et al. Among authors: oberste ms. Vaccine. 2018 Mar 20;36(13):1766-1771. doi: 10.1016/j.vaccine.2018.02.051. Epub 2018 Feb 21. Vaccine. 2018. PMID: 29477307 Free PMC article.

6

Poliovirus Type 2 Seroprevalence Following Full- or Fractional-Dose Inactivated Poliovirus Vaccine in the Period After Sabin Type 2 Withdrawal in Sri Lanka.

Gamage D, Mach O, Ginige S, Weldon WC, Oberste MS, Jeyaseelan V, Sutter RW. Gamage D, et al. Among authors: oberste ms. J Infect Dis. 2019 May 24;219(12):1887-1892. doi: 10.1093/infdis/jiz026. J Infect Dis. 2019. PMID: 30649505 Free PMC article.

7

Rapid Disappearance of Poliovirus Type 2 (PV2) Immunity in Young Children Following Withdrawal of Oral PV2-Containing Vaccine in Vietnam.

Huyen DTT, Mach O, Thanh Trung N, Thai PQ, Thang HV, Weldon WC, Oberste MS, Jeyaseelan V, Sutter RW, Anh DD. Huyen DTT, et al. Among authors: oberste ms. J Infect Dis. 2019 Jul 2;220(3):386-391. doi: 10.1093/infdis/jiz124. J Infect Dis. 2019. PMID: 30869149 Free PMC article.

8

Effect of buffer on the immune response to trivalent oral poliovirus vaccine in Bangladesh: a community based randomized controlled trial.

Chandir S, Ahamed KU, Baqui AH, Sutter RW, Okayasu H, Pallansch MA, Oberste MS, Moulton LH, Halsey NA. Chandir S, et al. Among authors: oberste ms. J Infect Dis. 2014 Nov 1;210 Suppl 1:S390-7. doi: 10.1093/infdis/jiu378. J Infect Dis. 2014. PMID: 25316860 Clinical Trial.

9

Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.

Verdijk P, Rots NY, van Oijen MG, Oberste MS, Boog CJ, Okayasu H, Sutter RW, Bakker WA. Verdijk P, et al. Among authors: oberste ms. Vaccine. 2013 Nov 12;31(47):5531-6. doi: 10.1016/j.vaccine.2013.09.021. Epub 2013 Sep 21. Vaccine. 2013. PMID: 24063976 Clinical Trial.

10

Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan.

Saleem AF, Mach O, Yousafzai MT, Khan A, Weldon WC, Oberste MS, Sutter RW, Zaidi AKM. Saleem AF, et al. Among authors: oberste ms. Vaccine. 2017 May 31;35(24):3209-3214. doi: 10.1016/j.vaccine.2017.04.075. Epub 2017 May 4. Vaccine. 2017. PMID: 28479178 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

254 results

Search Page

Filters